AXL receptor tyrosine kinase

BerGenBio Extends Phase II Trial With Bemcentinib and KEYTRUDA® in NSCLC to Include Patients With Disease Progression on Immune Checkpoint Inhibitor Therapy

Retrieved on: 
Tuesday, April 2, 2019
Medicine, Clinical medicine, Cancer treatments, Immune system, Cancer, AXL receptor tyrosine kinase, Checkpoint inhibitor, PD-L1, Bemcentinib, Immunotherapy, Immune checkpoint, PD-1 and PD-L1 inhibitors

Patients eligible to participate in Cohort B must have disease progression whilst on a therapy regimen which includes an anti-PD(L)1 inhibitor.

Key Points: 
  • Patients eligible to participate in Cohort B must have disease progression whilst on a therapy regimen which includes an anti-PD(L)1 inhibitor.
  • Comprehensive exploratory studies will evaluate biomarkers in tumour and blood indicative of AXL and PD-L1 expression as well as immune modulation.
  • Patients with AXL positive disease showed particularly good response rates, supporting our belief that selectively inhibiting AXL may act synergistically with immune checkpoint inhibitors in immunotherapy nave patients.
  • The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme.

BerGenBio Extends Phase II Trial With Bemcentinib and KEYTRUDA® in NSCLC to Include Patients With Disease Progression on Immune Checkpoint Inhibitor Therapy

Retrieved on: 
Tuesday, April 2, 2019
Medicine, Clinical medicine, Cancer treatments, Immune system, Cancer, AXL receptor tyrosine kinase, Checkpoint inhibitor, PD-L1, Bemcentinib, Immunotherapy, Immune checkpoint, PD-1 and PD-L1 inhibitors

Patients eligible to participate in Cohort B must have disease progression whilst on a therapy regimen which includes an anti-PD(L)1 inhibitor.

Key Points: 
  • Patients eligible to participate in Cohort B must have disease progression whilst on a therapy regimen which includes an anti-PD(L)1 inhibitor.
  • Comprehensive exploratory studies will evaluate biomarkers in tumour and blood indicative of AXL and PD-L1 expression as well as immune modulation.
  • Patients with AXL positive disease showed particularly good response rates, supporting our belief that selectively inhibiting AXL may act synergistically with immune checkpoint inhibitors in immunotherapy nave patients.
  • The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme.

BerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance

Retrieved on: 
Tuesday, April 2, 2019
Health sciences, Tyrosine kinase receptors, Health, Medicine, Protein kinase inhibitors, AXL receptor tyrosine kinase, Bemcentinib, Therapy, C-Met, Cancer, Combination therapy

The data presented lend further support to the Company's ongoing clinical proof-of-concept programme and planned late stage strategy evaluating bemcentinib's potential as a monotherapy and in combination across several indications.

Key Points: 
  • The data presented lend further support to the Company's ongoing clinical proof-of-concept programme and planned late stage strategy evaluating bemcentinib's potential as a monotherapy and in combination across several indications.
  • AXL inhibitors, therefore, have potential high value at the centre of cancer combination therapy, addressing significant unmet medical needs and multiple high-value market opportunities.
  • Increase in AXL function has been linked to key mechanisms of drug resistance and immune escape by tumour cells, leading to aggressive metastatic cancers.
  • BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers.

BerGenBio: Preclinical Data Presented at AACR Reinforces Bemcentinib's Potential to Reverse Tumour Immunosuppression and Therapy Resistance

Retrieved on: 
Tuesday, April 2, 2019
Health sciences, Tyrosine kinase receptors, Health, Medicine, Protein kinase inhibitors, AXL receptor tyrosine kinase, Bemcentinib, Therapy, C-Met, Cancer, Combination therapy

The data presented lend further support to the Company's ongoing clinical proof-of-concept programme and planned late stage strategy evaluating bemcentinib's potential as a monotherapy and in combination across several indications.

Key Points: 
  • The data presented lend further support to the Company's ongoing clinical proof-of-concept programme and planned late stage strategy evaluating bemcentinib's potential as a monotherapy and in combination across several indications.
  • AXL inhibitors, therefore, have potential high value at the centre of cancer combination therapy, addressing significant unmet medical needs and multiple high-value market opportunities.
  • Increase in AXL function has been linked to key mechanisms of drug resistance and immune escape by tumour cells, leading to aggressive metastatic cancers.
  • BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers.

Kanazawa University Research: Origin of Resistance to Lung-cancer Drug Discovered

Retrieved on: 
Thursday, March 21, 2019
Chemical compounds, Organic compounds, Medicine, Lung cancer, Pyrimidines, Tyrosine kinase receptors, Ethers, Indoles, Osimertinib, AXL receptor tyrosine kinase, Kanazawa University, Drug resistance

The combined application of osimertinib and an AXL inhibitor is shown to limit intrinsic resistance to the drug.

Key Points: 
  • The combined application of osimertinib and an AXL inhibitor is shown to limit intrinsic resistance to the drug.
  • However, in some patients, intrinsic resistance and inadequate response to osimertinib has been seen to occur.Seiji Yano from Kanazawa University and colleagues have now discovered that a particular protein known as AXL causes the resistance to osimertinib and the emergence of osimertinib-tolerant cells.
  • The University is located on the coast of the Sea of Japan in Kanazawa a city rich in history and culture.
  • Kanazawa University is divided into two main campuses: Kakuma and Takaramachi for its approximately 10,200 students including 600 from overseas.

Kanazawa University Research: Origin of Resistance to Lung-cancer Drug Discovered

Retrieved on: 
Thursday, March 21, 2019
Chemical compounds, Organic compounds, Medicine, Lung cancer, Pyrimidines, Tyrosine kinase receptors, Ethers, Indoles, Osimertinib, AXL receptor tyrosine kinase, Kanazawa University, Drug resistance

The combined application of osimertinib and an AXL inhibitor is shown to limit intrinsic resistance to the drug.

Key Points: 
  • The combined application of osimertinib and an AXL inhibitor is shown to limit intrinsic resistance to the drug.
  • However, in some patients, intrinsic resistance and inadequate response to osimertinib has been seen to occur.Seiji Yano from Kanazawa University and colleagues have now discovered that a particular protein known as AXL causes the resistance to osimertinib and the emergence of osimertinib-tolerant cells.
  • The University is located on the coast of the Sea of Japan in Kanazawa a city rich in history and culture.
  • Kanazawa University is divided into two main campuses: Kakuma and Takaramachi for its approximately 10,200 students including 600 from overseas.

BerGenBio Appoints Cancer Drug Development Specialist Alan Barge MD as Interim Chief Medical Officer

Retrieved on: 
Wednesday, November 21, 2018
Amgen, AstraZeneca, AXL receptor tyrosine kinase, Protein kinase inhibitor, Oncology, Business, Biotechnology, Health

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, oral, selective AXL kinase inhibitors for multiple cancer indications, is delighted to announce the appointment of Alan Barge MD as Interim Chief Medical Officer and member of the leadership team.

Key Points: 
  • BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, oral, selective AXL kinase inhibitors for multiple cancer indications, is delighted to announce the appointment of Alan Barge MD as Interim Chief Medical Officer and member of the leadership team.
  • Dr Barge is a board-certified oncologist and haematologist, with more than 25 years of experience in cancer drug development, spent primarily at AstraZeneca and Amgen.
  • Prior to AZ, Dr Barge was European and Global Medical Director at Amgen, at which he was responsible for European approval and label extensions for several of Amgen's cancer therapies.
  • Dr Barge will work as part of BerGenBio's leadership team on an interim basis until a permanent CMO is appointed.

BerGenBio Appoints Cancer Drug Development Specialist Alan Barge MD as Interim Chief Medical Officer

Retrieved on: 
Wednesday, November 21, 2018
Amgen, AstraZeneca, AXL receptor tyrosine kinase, Protein kinase inhibitor, Oncology, Business, Biotechnology, Health

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, oral, selective AXL kinase inhibitors for multiple cancer indications, is delighted to announce the appointment of Alan Barge MD as Interim Chief Medical Officer and member of the leadership team.

Key Points: 
  • BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, oral, selective AXL kinase inhibitors for multiple cancer indications, is delighted to announce the appointment of Alan Barge MD as Interim Chief Medical Officer and member of the leadership team.
  • Dr Barge is a board-certified oncologist and haematologist, with more than 25 years of experience in cancer drug development, spent primarily at AstraZeneca and Amgen.
  • Prior to AZ, Dr Barge was European and Global Medical Director at Amgen, at which he was responsible for European approval and label extensions for several of Amgen's cancer therapies.
  • Dr Barge will work as part of BerGenBio's leadership team on an interim basis until a permanent CMO is appointed.

Tolero Pharmaceuticals Presents Clinical Data of AXL Kinase Inhibitor TP-0903 Showing its Ability to Enhance Host Immune Responses to Tumors

Retrieved on: 
Thursday, November 15, 2018
Tyrosine kinase receptors, AXL receptor tyrosine kinase, Immunology, Biology, Immune system, Stem cells, Induced stem cells, Draft:All-trans retinoic acid and treatement of solid tumor

Key findings from syngeneic mouse models suggest that TP-0903 has immune activating potential leading to enhanced host immune responses in tumor models.

Key Points: 
  • Key findings from syngeneic mouse models suggest that TP-0903 has immune activating potential leading to enhanced host immune responses in tumor models.
  • Preclinical models in immune competent animals show modulation of immune cell populations, including neutrophils, regulatory T-cells, and dendritic cells, in the tumors.
  • Recent data suggest that AXL kinase is involved in tumor cell proliferation and development of resistance to chemotherapeutics.
  • Inhibition of Axl kinase reverses the mesenchymal phenotype in leukemic cells through the disruption of retinoic signaling [Abstract].Blood.

BerGenBio Announces Interim Biomarker and Phase II Clinical Data With Selective AXL Inhibitor Bemcentinib Presented at ESMO

Retrieved on: 
Monday, October 22, 2018
Protein kinase inhibitors, AXL receptor tyrosine kinase, Bemcentinib, Axl, Chemistry

BERGEN, Norway, Oct. 22, 2018 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO) announces that the company and its collaborators have presented interim clinical and biomarker data from BerGenBio's Phase II clinical programme with bemcentinib (BGB324), a first-in-class highly selective oral AXL inhibitor, at the ESMO 2018 Congress in Munich (19 - 23 October 2018).

Key Points: 
  • BERGEN, Norway, Oct. 22, 2018 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO) announces that the company and its collaborators have presented interim clinical and biomarker data from BerGenBio's Phase II clinical programme with bemcentinib (BGB324), a first-in-class highly selective oral AXL inhibitor, at the ESMO 2018 Congress in Munich (19 - 23 October 2018).
  • The data show that AXL is upregulated in MDS patients and that inhibiting AXL with bemcentinib shows efficacy in pre-clinical models of the disease.
  • Additionally, data presented at ESMO continue to show that bemcentinib is well tolerated and effective across our broad Phase II combination programme.
  • The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme.